➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Mallinckrodt
Express Scripts
Boehringer Ingelheim
Colorcon

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,265,760


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,265,760 protect, and when does it expire?

Patent 9,265,760 protects ZOHYDRO ER and is included in one NDA.

This patent has six patent family members in four countries.

Summary for Patent: 9,265,760
Title:Treating pain in patients with hepatic impairment
Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment.
Inventor(s): Hartman; Andrew (Belmont, CA), Rubino; Christopher M. (Williamsville, NY), Robinson; Cynthia Y. (Burlingame, CA)
Assignee: Pemix Ireland Pain Limited (Dublin, IE)
Application Number:14/815,219
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,265,760
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form; Device;

Drugs Protected by US Patent 9,265,760

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-001 Oct 25, 2013 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT ⤷  Free Forever Trial
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-002 Oct 25, 2013 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT ⤷  Free Forever Trial
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-003 Oct 25, 2013 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT ⤷  Free Forever Trial
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-004 Oct 25, 2013 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT ⤷  Free Forever Trial
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-005 Oct 25, 2013 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT ⤷  Free Forever Trial
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-006 Oct 25, 2013 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,265,760

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2872677 ⤷  Free Forever Trial
China 103904260 ⤷  Free Forever Trial
China 105759918 ⤷  Free Forever Trial
Japan 2014127347 ⤷  Free Forever Trial
Japan 6089296 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2014022570 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
AstraZeneca
Harvard Business School
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.